A 40-month multicentre, randomised placebo-controlled study to assess the efficacy and carry-over effect of repeated intra-articular injections of hyaluronic acid in knee osteoarthritis: the AMELIA project

F Navarro-Sarabia, P Coronel, E Collantes, F J Navarro, A Rodriguez de la Serna, A Naranjo, M Gimeno, G Herrero-Beaumont, AMELIA study group, J Toyos, B Hernández-Cruz, J Belzunegui, S García, M E Brito, J C Acebes, J L Guerra, J Pujol, F Blanco, P Benito, E Chamizo, F A Martínez, R García, M Guzmán, M García, J Mulero, F Navarro-Sarabia, P Coronel, E Collantes, F J Navarro, A Rodriguez de la Serna, A Naranjo, M Gimeno, G Herrero-Beaumont, AMELIA study group, J Toyos, B Hernández-Cruz, J Belzunegui, S García, M E Brito, J C Acebes, J L Guerra, J Pujol, F Blanco, P Benito, E Chamizo, F A Martínez, R García, M Guzmán, M García, J Mulero

Abstract

Objective: AMELIA (OsteoArthritis Modifying Effects of Long-term Intra-articular Adant) was designed to compare against placebo the efficacy and safety of repeated injections of hyaluronic acid (HA) and its effect on disease progression over 40 months.

Methods: A multicentre, randomised, patient and evaluator-blinded, controlled study in 306 patients fulfilling American College of Rheumatology criteria for knee osteoarthritis, radiological grades II-III (Kellgren-Lawrence) and joint space width ≥ 2 mm. Patients received four cycles of five intra-articular HA or placebo injections with a follow-up of 6 months after the first and second cycles, and 1 year after the third and fourth cycles. Osteoarthritis Research Society International (OARSI) 2004 responder criteria were used to assess efficacy. The consumption of rescue medication was a secondary outcome. Adverse events were recorded for safety purposes.

Results: At the 40-month visit significantly more patients responded to HA compared with placebo (OARSI 2004, p=0.004). The number of responders to HA increased through the study, whereas those to placebo did not change. Significant differences were also found in favour of HA for each individual component of the OARSI 2004. No safety problems were recorded.

Conclusions: The results of AMELIA offer pioneer evidence that repeated cycles of intra-articular injections of HA not only improve knee osteoarthritis symptoms during the in-between cycle period but also exert a marked carry-over effect for at least 1 year after the last cycle. In this respect, it is not possible to establish if this carry-over effect reflects true osteoarthritis remission or just a modification of the disease's natural course. ClinicalTrials.gov number, NCT00669032.

Conflict of interest statement

Competing interests PC and MG work at Tedec Meiji Farma SA. The other authors received research funds from Tedec Meiji Farma SA as study investigators.

Figures

Figure 1
Figure 1
Study diagram. HA, hyaluronic acid; i.a., intra-articular.
Figure 2
Figure 2
Patients' disposition for clinical assessment. JSW, joint space width.
Figure 3
Figure 3
Evolution of responders Osteoarthritis Research Society International, 2004. HA, hyaluronic acid.

References

    1. Herrero-Beaumont G, Roman-Blas JA, Castañeda S, et al. Primary osteoarthritis no longer primary: three subsets with distinct etiological, clinical, and therapeutic characteristics. Semin Arthritis Rheum 2009;39:71–80
    1. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60:91–7
    1. Fam H, Bryant JT, Kontopoulou M. Rheological properties of synovial fluids. Biorheology 2007;44:59–74
    1. Ghosh P, Guidolin D. Potential mechanism of action of intra-articular hyaluronan therapy in osteoarthritis: are the effects molecular weight dependent? Semin Arthritis Rheum 2002;32:10–37
    1. Greenberg DD, Stoker A, Kane S, et al. Biochemical effects of two different hyaluronic acid products in a co-culture model of osteoarthritis. Osteoarthritis Cartilage 2006;14:814–22
    1. Karna E, Miltyk W, Palka JA, et al. Hyaluronic acid counteracts interleukin-1-induced inhibition of collagen biosynthesis in cultured human chondrocytes. Pharmacol Res 2006;54:275–81
    1. Takahashi K, Goomer RS, Harwood F, et al. The effects of hyaluronan on matrix metalloproteinase-3 (MMP-3), interleukin-1 beta (IL-1beta), and tissue inhibitor of metalloproteinase-1 (TIMP-1) gene expression during the development of osteoarthritis. Osteoarthritis Cartilage 1999;7:182–90
    1. Takahashi K, Hashimoto S, Kubo T, et al. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol 2000;27:1713–20
    1. Waddell DD, Kolomytkin OV, Dunn S, et al. Hyaluronan suppresses IL-1beta-induced metalloproteinase activity from synovial tissue. Clin Orthop Relat Res 2007;465:241–8
    1. Bruyère O, Burlet N, Delmas PD, et al. Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system. BMC Musculoskelet Disord 2008;9:165.
    1. Dougados M. Symptomatic slow-acting drugs for osteoarthritis: what are the facts? Joint Bone Spine 2006;73:606–9
    1. Altman RD, Hochberg MC, Moskowitz RW, et al. Recommendations for the medical management of osteoarthritis of the hip and knee. 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000;43:1905–15
    1. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003;62:1145–55
    1. The National Collaborating Centre for Chronic Conditions Osteoarthritis: National Clinical Guideline for Care and Management in Adults. London: Royal College of Physicians, 2008
    1. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62
    1. Prieto JG, Pulido MM, Zapico J, et al. Comparative study of hyaluronic derivatives: rheological behaviour, mechanical and chemical degradation. Int J Biol Macromol 2005;35:63–9
    1. Sánchez-Lázaro J, Díaz-Gállego L. The clinical impact of physical-chemical characteristics of different hyaluronic acids as a treatment for osteoarthritis. Int J Biol Macromol 2006;38:300–1
    1. Altman R, Asch E, Bloch D, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum 1986;29:1039–49
    1. Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957;16:494–502
    1. Pham T, van der Heijde D, Altman RD, et al. OMERACT–OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004;12:389–99
    1. Arrich J, Piribauer F, Mad P, et al. Intra-articular hyaluronic acid for the treatment of osteoarthritis of the knee: systematic review and meta-analysis. Can Med Assoc J 2005;172:1039–43
    1. Bannuru RR, Natov NS, Obadan IE, et al. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum 2009;61:1704–11
    1. Bellamy N, Campbell J, Welch V, et al. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005321.
    1. Lo GH, LaValley M, McAlindon T, et al. Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 2003;290:3115–21
    1. Modawal A, Ferrer M, Choi HK, et al. Hyaluronic acid injections relieve knee pain. J Fam Pract 2005;54:758–67
    1. Wang CT, Lin J, Chang CJ, et al. Therapeutic effects of hyaluronic acid on osteoarthritis of the knee. A meta-analysis of randomized controlled trials. J Bone Joint Surg Am 2004;86-A:538–45
    1. Jørgensen A, Stengaard-Pedersen K, Simonsen O, et al. Intra-articular hyaluronan is without clinical effect in knee osteoarthritis: a multicentre, randomised, placebo-controlled, double-blind study of 337 patients followed for 1 year. Ann Rheum Dis 2010;69:1097–102
    1. Band PA. OARSI update on the evidence for osteoarthritis therapies: comment on the nomenclature used for intra-articular hyaluronan. Osteoarthritis Cartilage 2010;18:1235; author reply 1236
    1. Altman RD, Moskowitz R. Intraarticular sodium hyaluronate (Hyalgan) in the treatment of patients with osteoarthritis of the knee: a randomized clinical trial. Hyalgan Study Group. J Rheumatol 1998;25:2203–12
    1. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795–808
    1. Smith MD, Wetherall M, Darby T, et al. A randomized placebo-controlled trial of arthroscopic lavage versus lavage plus intra-articular corticosteroids in the management of symptomatic osteoarthritis of the knee. Rheumatology (Oxford) 2003;42:1477–85
    1. Zhang W, Robertson J, Jones AC, et al. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis 2008;67:1716–23
    1. Bellamy N, Campbell J, Robinson V, et al. Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006;2:CD005328

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅